Inspira Technologies Oxy BHN (IINN)
NASDAQ:IINN
IINN Stock Chart & Stats
$0.96
-$0.05(-4.95%)
At close: 4:00 PM EST
$0.96
-$0.05(-4.95%)
Day’s Range― - ―
52-Week Range$0.34 - $1.65
Previous CloseN/A
Volume61.41K
Average Volume (3M)330.47K
Market Cap
$17.01M
Enterprise Value$7.98M
Total Cash (Recent Filing)$2.13M
Total Debt (Recent Filing)$640.00K
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding43,271,835
10 Day Avg. Volume227,613
30 Day Avg. Volume330,466
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)11.48
Price to Sales (P/S)92.25
P/FCF Ratio-2.68
Enterprise Value/Market Cap0.47
Enterprise Value/Revenue27.62
Enterprise Value/Gross Profit3.99K
Enterprise Value/Ebitda-1.11
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.11
Revenue Forecast (FY)$48.00M
Bulls Say, Bears Say
Bulls Say
FDA-cleared ART100 Deployed In Tier-1 HospitalFDA clearance plus integration into a leading academic center's clinical workflow is a durable commercialization milestone. Structured evaluations that define clinical protocols increase the likelihood of repeat institutional purchases and broaden adoption pathways over the next 2–6 months, converting pilot use into recurring procurement.
Clalit Vendor Approval Opens Large Procurement ChannelClalit vendor status provides validation from a rigorous health system and immediate access to 14 hospitals and 1,600 clinics. That structural channel can generate sustained order flow, create a powerful reference case for other payers/hospitals, and materially support sales traction over multiple quarters.
Validated Standalone HYLA Sensor With Strong AccuracyDecoupling HYLA into a universal, standalone sensor targets a large heart-lung surgery market and enables a recurring consumables and software revenue model. This creates a higher-margin, scalable product stream that can leverage installed OR/ICU bases and support durable revenue diversification beyond capital equipment sales.
Bears Say
Minimal And Unstable Revenue; Negative MarginsVery low revenue and negative gross profit indicate the company has not yet achieved product-driven profitability or operating leverage. Persistent large operating losses reduce runway, constrain reinvestment in commercialization, and make multi-quarter growth projections harder to underwrite without sustainable margin improvement.
Persistent Heavy Cash BurnSustained negative operating and free cash flow, with free cash flow worsening in 2025, implies ongoing reliance on external financing. That cash-burn profile pressures strategic flexibility, increases dilution risk from future raises, and limits the company's ability to scale commercial operations without recurring funding rounds.
Nasdaq Listing Non-compliance RiskA formal Nasdaq non-compliance notice creates structural regulatory and financing risk: failure to regain compliance could jeopardize U.S. listing status, impair access to U.S. capital markets, and force hurried dilutive financings or strategic concessions, all of which can materially constrain long-term commercial execution.
Inspira Technologies Oxy BHN News
IINN FAQ
What was Inspira Technologies Oxy BHN’s price range in the past 12 months?
Inspira Technologies Oxy BHN lowest stock price was $0.34 and its highest was $1.65 in the past 12 months.
What is Inspira Technologies Oxy BHN’s market cap?
Inspira Technologies Oxy BHN’s market cap is $17.01M.
When is Inspira Technologies Oxy BHN’s upcoming earnings report date?
Inspira Technologies Oxy BHN’s upcoming earnings report date is Aug 06, 2026 which is in 131 days.
How were Inspira Technologies Oxy BHN’s earnings last quarter?
Inspira Technologies Oxy BHN released its earnings results on Mar 26, 2026. The company reported -$0.207 earnings per share for the quarter, missing the consensus estimate of -$0.2 by -$0.007.
Is Inspira Technologies Oxy BHN overvalued?
According to Wall Street analysts Inspira Technologies Oxy BHN’s price is currently Overvalued.
Does Inspira Technologies Oxy BHN pay dividends?
Inspira Technologies Oxy BHN does not currently pay dividends.
What is Inspira Technologies Oxy BHN’s EPS estimate?
Inspira Technologies Oxy BHN’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Inspira Technologies Oxy BHN have?
Inspira Technologies Oxy BHN has 43,271,835 shares outstanding.
What happened to Inspira Technologies Oxy BHN’s price movement after its last earnings report?
Inspira Technologies Oxy BHN reported an EPS of -$0.207 in its last earnings report, missing expectations of -$0.2. Following the earnings report the stock price went down -23.092%.
Which hedge fund is a major shareholder of Inspira Technologies Oxy BHN?
Currently, no hedge funds are holding shares in IINN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Inspira Technologies Oxy BHN
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
4.23% Other Institutional Investors
95.76% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---